Epoetin kappa - JCR Pharmaceuticals

Drug Profile

Epoetin kappa - JCR Pharmaceuticals

Alternative Names: Epoetin alfa biosimilar - JCR Pharmaceuticals/Kissei Pharmaceuticals; Epoetin alfa biosimilar 1; Epoetin Alfa BS Injection [JCR]; Epoetin Alpha BS Inj. JCR; JR-013

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator JCR Pharmaceuticals
  • Developer JCR Pharmaceuticals; Kissei Pharmaceutical
  • Class Antianaemics; Haematopoietic cell growth factors; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Anaemia

Most Recent Events

  • 27 May 2010 Launched for Anaemia (in neonates) in Japan (SC) - first global launch
  • 27 May 2010 Launched for Anaemia (renal anaemia in patients undergoing dialysis) in Japan (IV) - first global launch
  • 20 Jan 2010 Registered for Anaemia (in neonates) in Japan (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top